Delamanid + Bedaquiline + Optimized Background Regimen (OBR)
Treatment for Hiv Aids Extensively Drug Resistant Tuberculosis
Typical Dosage: Delamanid: 100mg twice daily (6 months); Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); OBR drugs (e.g., Clofazimine 100mg daily, Cycloserine 250-500mg twice daily)
Effectiveness
75%
Safety Score
32%
Clinical Trials
15
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
32
DangerousModerateSafe
Treatment Details
Dosage Range
Delamanid: 100mg twice daily (6 months); Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); OBR drugs (e.g., Clofazimine 100mg daily, Cycloserine 250-500mg twice daily)
Time to Effect
2-3 months (sputum conversion), 3-6 months (clinical improvement)
Treatment Duration
18-24 months
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$53,000
Monitoring:$7,000
Side Effect Mgmt:$8,000
Total Annual:$68,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$11,333/QALY
QALYs Gained
6
Outcome-Based Costs
Cost per Responder
$90,667
Cost per Remission
$90,667
Comparison vs Individualized regimen without novel drugs or with injectables
Cost Difference
+$10,000/year
More expensive
QALY Difference
+1.50 QALYs
Better outcomes
Dominance
No dominance
Delamanid + Bedaquiline + Optimized Background Regimen (OBR) Outcomes
for Hiv Aids Extensively Drug Resistant Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+75%
Common Side Effects
QT prolongation
+20%
Hepatotoxicity
+15%
Skin discoloration (from Clofazimine in OBR)
+90%
Gastrointestinal issues
+30%
Neuropsychiatric effects (from Cycloserine in OBR)
+25%
Peripheral neuropathy
+10%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov